Sylvester Comprehensive Cancer Center, University of Miami | Strategic Alliance Partners

The research offers an early view into challenges that health systems across the globe will likely face as extreme heat becomes more common.

In the phase 3 RECITE trial, romiplostim significantly reduced chemotherapy dose modifications due to thrombocytopenia vs placebo in gastrointestinal cancers.

Gerald Soff, MD, discusses data from the phase 3 RECITE trial showing that romiplostim reduces chemotherapy dose modifications in patients with GI cancer.

Coral Olazagasti, MD, discusses the significance of providing resources to oncology physicians who are looking to strengthen their overall wellness.

Researchers found machine learning models using patient-reported outcomes and clinical data could help forecast unplanned health care use after treatment.

Gerald Soff, MD, discusses how romiplostim could improve long-term outcomes in patients with GI cancer and thrombocytopenia by preserving relative dose intensity.

Mario Sznol, MD, discusses current guidance around the use of neoadjuvant therapy in advanced melanoma.

Mario Sznol, MD, discusses the challenges of determining whether to recommend adjuvant therapy for patients with melanoma based on current data.

Mario Sznol, MD, discusses the uncertainties around predicting benefit with immune checkpoint inhibitors in metastatic melanoma.

Mario Sznol, MD, discusses long-term melanoma survival, treatment gaps after progression, and emerging strategies for resistant disease.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HER2+ breast cancer, pancreatic cancer, colorectal cancer, and melanoma.

Mario Sznol, MD, discusses the current therapeutic landscape in the frontline setting for patients with advanced or metastatic melanoma.

A large U.S. study showed that adults who have never been married face a significantly higher risk of developing cancer than those who have been married.

A study identified genetic mutations tied to earlier diagnosis and faster progression of myelodysplastic syndromes.

C. Ola Landgren, MD, PhD, discusses the development of the AI risk-stratification model CORAL and its potential role in individualizing myeloma care.

C. Ola Landgren, MD, PhD, discusses evolving risk-stratification strategies in honor of Multiple Myeloma Awareness Month.

Serial liquid biopsies consistently showed AR alterations linked to poorer outcomes, and findings support “real-time” molecular testing to guide personalized care.

Obrixtamig plus platinum chemo showed a 72% response rate and manageable safety in frontline DLL3-positive NEC in the phase 1 DAREON-7 trial.

The new facility doubles Sylvester’s research footprint, breaking down barriers between scientific research and patient care.

A group of researchers from the University of Miami sought to understand why many clinical trials in head and neck cancers fail.

Two gene mutations, IDH2 and SRSF2, work together to disrupt RNA editing, changing how blood cells develop in acute myeloid leukemia

A new study presented at the 2025 ASH Annual Meeting revealed that subtle disruptions in genome architecture can predispose individuals to lymphoma.

Researchers at Sylvester Comprehensive Cancer Center lead the way in innovative AML treatments.

Erdafitinib had a safety profile that was deemed tolerable in patients with recurrent or progressive IDH wild-type glioma harboring F3T3 gene fusions.

Estelamari Rodriguez, MD, MPH, Coral Olazagasti, MD, and Tina Roy, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.

Loncastuximab tesirine plus glofitamab demonstrated early promise in patients with relapsed or refractory large B-cell lymphoma.

Gina Z. D’Amato, MD, discusses the rationale for investigating olaparib plus temozolomide in previously treated advanced uterine leiomyosarcoma.

The novel targeted drug olutasidenib has been shown to be effacacious in select patients with MDS.

The top 5 OncLive videos of the week cover insights in lung cancer, myelofibrosis, and mantle cell lymphoma.

New study takes a deep dive into how TAF1 operates to promote development of new blood cells.